<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416427</url>
  </required_header>
  <id_info>
    <org_study_id>637/15</org_study_id>
    <nct_id>NCT02416427</nct_id>
  </id_info>
  <brief_title>Targeting the Hippo Transducer TAZ in Breast Cancer With Statins</brief_title>
  <acronym>TRINACRIA</acronym>
  <official_title>A Phase II, Randomized, Non-comparative, Pre-surgical Study of Atorvastatin or Observation in Ki-67 Positive, TAZ-expressing Early Breast Cancer Patients (TRINACRIA Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Elena Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regina Elena Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pre-surgical, window-of-opportunity study is designed to investigate whether&#xD;
      atorvastatin reduces the proliferation marker Ki-67 via modulation of the Hippo transducer&#xD;
      TAZ.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ki-67 reduction below the 15% (marker response).</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Decreased TAZ expression</measure>
    <time_frame>4 weeks</time_frame>
    <description>Reduced TAZ expression evaluated by IHC when comparing pre- and post-treatment samples. Staining intensity will be graded on a four-grade scale (0: negative, 1: weak, 2: moderate, 3: strong). The final score will be obtained by considering staining intensity, percentage of expressing cells, and localization (nuclear versus cytoplasmic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathway inhibition</measure>
    <time_frame>4 weeks</time_frame>
    <description>Decreased expression of TAZ targets (AXL and CTGF) and Atorvastatin target (HMGCoAR) evaluated by IHC when comparing pre- and post-treatment samples. Staining intensity for all the molecular endpoints analyzed will be graded on a four-grade scale (0: negative, 1: weak, 2: moderate, 3: strong).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 80 mg/day for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Female aged &gt;18 years and &lt;75 years at the time of the enrolment&#xD;
&#xD;
          -  Histologically confirmed Breast Cancer (BC) independently on the intrinsic subtype&#xD;
&#xD;
          -  Stage I-IIa BC patients candidate for elective surgery&#xD;
&#xD;
          -  BC expressing Ki-67 ≥ 15% and TAZ &gt; 10% in diagnostic core biopsies&#xD;
&#xD;
          -  Adequate baseline organ function&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Previous systemic therapy including chemotherapy, hormone therapy and targeted agents&#xD;
&#xD;
          -  Administration of an investigational drug prior to enrolment&#xD;
&#xD;
          -  History of another malignancy, except for a history of completely resected&#xD;
             non-melanoma skin cancer or successfully treated cervical in situ carcinoma&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≥2&#xD;
&#xD;
          -  Subjects who have current active hepatic or biliary disease (with exception of&#xD;
             patients with Gilbert's syndrome and asymptomatic gallstones)&#xD;
&#xD;
          -  Serious cardiac illness or medical conditions including but not confined to: history&#xD;
             of documented congestive heart failure (CHF) or systolic dysfunction (LVEF &lt;50%);&#xD;
             high-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV-block,&#xD;
             supraventricular arrhythmias which are not adequately controlled); angina pectoris&#xD;
             requiring antianginal medication; clinically significant valvular heart disease;&#xD;
             evidence of transmural infarction on ECG; poorly controlled hypertension (e.g.&#xD;
             systolic &gt;180mm Hg or diastolic &gt;100mm Hg)&#xD;
&#xD;
          -  Have a concurrent disease or condition that may interfere with study participation, or&#xD;
             any serious medical disorder that would interfere with the subject's safety (for&#xD;
             example, active or uncontrolled infection or any psychiatric condition prohibiting&#xD;
             understanding or rendering of informed consent)&#xD;
&#xD;
          -  Current or recent therapy with statins for hypercholesterolemia or other&#xD;
             lipid-lowering drugs&#xD;
&#xD;
          -  Current or recent therapy with glucose-lowering drugs for diabetes&#xD;
&#xD;
          -  Current or recent therapy with strong CYP3A4 inhibitors (e.g., clarithromycin, HIV&#xD;
             protease inhibitors, itraconazole) given potential interactions with atorvastatin&#xD;
&#xD;
          -  Current or recent therapy with gemfibrozil or other fibrates given potential&#xD;
             interactions with atorvastatin.&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marcello Maugeri Saccà, MD</last_name>
    <phone>+39065266</phone>
    <phone_ext>2724</phone_ext>
    <email>maugeri@ifo.it</email>
  </overall_contact>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regina Elena Cancer Institute</investigator_affiliation>
    <investigator_full_name>Dr. Marcello Maugeri-Saccà</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Atorvastatin</keyword>
  <keyword>TAZ</keyword>
  <keyword>Hippo pathway</keyword>
  <keyword>ki67</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

